ICo Therapeutics Ltd. (TSXV:ICO) ICo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. ICo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases.
With the recent significant news that the Company's U.S. patent 8,592,382 was issued for the Oral Amphotericin B platform (Oral AmpB) providing protection around oral delivery of the drug, excitement and anticipation is building! With the recent receipt of ethics approval, the Oral AmpB technology is also moving into in vitro testing with study partners in Montreal, and will examine the role of this formulation in targeting latent HIV reservoirs which remain in individuals despite enormous therapeutic advances in the treatment of HIV/AIDS. ICo is poised to start making licensing announcements with major pharmaceutical companies across the globe. These are milestones which biotech analysts have been expecting for years.
The good news is that there still seems to be a bit of time to get in before the next major milestone achievements happen. The first big announcement should involve the successful results of the Phase 2 trials, expected in March or April 2014. That the company has just started trading on the prestigious OTCQX does not seem to be a coincidence in any way at all. In fact, insiders suggest this is a deliberate move to gain traction in the US markets before the major announcements are made!
And from the company's website, check out this excitement either completed or about to be completed:
RECENT & UPCOMING MILESTONES
iCo-007 for Diabetes Related Blindness
33 Phase 1 trial complete with encouraging efficacy trends
33 Complete "fill finish" manufacturing program to produce clinical supply
33 Phase 2 clinical trial in the U.S. initiated
33 Phase 2 Research Collaboration with JDRF
33 Phase 2 iDEAL study clinical update
❑ Phase 2 iDEAL study primary endpoint
❑ Phase 2 iDEAL study secondary endpoints
❑ Ongoing regional partnership discussions
iCo-008 for Sight Threatening Diseases
33 License systemic rights to Immune Pharma for $32 million+
❑ Pursuing non-dilutive funding for ocular programs
Oral Amphotericin B Delivery System
33 FDA Pre-IND meeting - iCo has plan to move forward
33 Orphan Drug Status received for Visceral Leishmaniasis
33 Approximately $2 million in non-dilutive funding received
(CPDD/Gates Foundation and CIHR)
33 Robust Scientific Advisory Board Assemble
❑ In vitro testing in Q2 2013
❑ Ongoing partnership discussions
Add to any of these licensing agreements a surprise news announcement or two, combined with competing large pharmaceuticals wanting to license the same technology so as not to fall behind the competition and ICo Therapeutics could be the one that gets away. Don't risk missing this! Take a flier on ICo Therapeutics soon! This could be the next ten-bagger in the making! ICo Therapeutics has been silently going about its work and very soon will be a name everyone is talking about. Do NOT pass up the chance of a lifetime!
Disclosure: I am long ICOTF, .